Teva launches new generic Pulmicort Respules dosage strength

JERUSALEM — Teva on Wednesday announced the U.S. launch of the 1-mg/2-ml dosage strength of its generic Pulmicort Respules (budesonide inhalation suspension). 

 

With the launch, the company completes its portfolio of Pulmicort Respules generics, having previously launched it in strengths of 0.25/2 ml and 0.5 mg/2 ml. The drug is indicated to control and prevent asthma symptoms in children aged 1 to 8 year. 

 

Pulmicort Respules saw U.S. sales of $217 million for the 12 months ended November 2015, according to IMS Health.